Advanced Cell Diagnostics (Hayward, CA), a clinical-stage biotechnology company focused on diagnostics and development of therapeutics for Age-related Macular Degeneration and Stargardt’s Macular Dystrophy, closed a $12M Series B financing. Participants include New Leaf Venture Partners and Morningside Ventures. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled Comprehensive and Accurate Access […]
Promedior (Malvern, PA), a clinical-stage biotechnology company focused on Age-Related Macular Degeneration, closed a $3M Series D financing, bringing the total round to $24.5M. Participants include Shire Strategic Investment Group, Fibrotec Ventures, Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, Forbion Capital Partners and Easton Capital Investment Group. Collective IP | The Most Comprehensive and Accurate […]
VisionCare Ophthalmic Technologies (Saratoga, CA) a commercial-stage medical device company focused on advanced age-related macular degeneration, closed a $31M Series E financing. Participants include Saints Venture Capital, Giza Ventures, Generali Financial Holdings, BSI, Pitango Venture Capital, Three Arch Partners, Onset Ventures and Infinity CSVC Management.
Taligen Therapeutics (Aurora, CO) a development stage biotechnology company focused on the treatment of serious inflammatory diseases including asthma, macular degeneration and immune kidney disease closed a $65M Series B financing. Participants include Alta Partners, Clarus Ventures, Sanderling Ventures, Tango and High Country Venture.